AHA/ACC preventive cardiology, dyslipidemia & epi (Lp(a)/LDL goals, PREVENT, menopause, visceral fat HF); aggressive LDL<55; HTN advances; new chol guidelines +HCM/arrhy
Key Questions
What risk reductions were associated with the Shingrix vaccine?
Shingrix vaccine reduced MACE by 46%, death by 66%, and dementia by 33% including Alz/vasc risks in a large Medicare study.
How do ultra-processed foods (UPF) impact heart disease and AFib risk?
UPF consumption raised heart disease risk by 19%, AFib, and multimorbidity. Experts recommend limiting UPF to lower these risks.
What did the SAMSON trial reveal about statin nocebo effects?
The SAMSON trial debunked statin nocebo effects, ending 30 years of panic with evidence supporting their safety.
What are the AHA's 10 key factors to lower dementia and stroke risk?
AHA identified 10 factors like healthy diet and lifestyle habits to cut dementia and stroke risk.
What were the Phase 3 results of aficamten in HCM?
Aficamten achieved dual efficacy goals in the ACACIA-HCM Phase 3 trial for hypertrophic cardiomyopathy (HCM).
Did Lilly's Foundayo pill reduce CVD events?
Lilly's Foundayo pill lowered heart attack and stroke risk by 16% in a trial of 2,700 patients.
How do heart rate extremes and lifestyle affect stroke risk?
Very low (<50 bpm) or high heart rates increased stroke risk by 25%; single tests, lifestyle, and more steps lower risks.
What new targets like Lp(a) and aggressive LDL goals are highlighted?
Aggressive LDL <55 mg/dL is recommended; Lp(a) therapies include VERVE, obicetrapib, enlicitide. Portfolio/LE8 support prevention.
Shingrix vax MACE46%/death66%/dem33% Alz/vasc; UPF 19%HD/AFib/multimorb; statin nocebo debunk SAMSON; AHA 10 factors dem/stroke cut; CBT menopause; prior Lilly Foundayo 16%CVD; aficamten Ph3 HCM dual; single-test/lifestyle/HR stroke; Portfolio/LE8; Lp(a)/VERVE/obicetrapib/enlicitide; statin<55.